HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies
International Journal of Molecular Sciences · 22.05.2026 · 27 (11) · 4673
DOI: 10.3390/ijms27114673 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.05.2026. Verfasst von Alexandra Georgiana Scurtu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Stomach Neoplasms, Adenocarcinoma, Esophagogastric Junction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FOCUS: Training and Guidance for UMFST Researchers in Health, European Union.
Abstract (Originalsprache)
Human epidermal growth factor receptor 2 (HER2) dysregulation contributes to tumorigenesis in gastric and gastroesophageal junction adenocarcinomas (GC/GEJ). HER2 overexpression has been associated in multiple cohorts with aggressive behavior and poor outcomes. While HER2 amplification has long guided therapy in HER2-positive disease, antibody–drug conjugates (ADCs) have shifted attention toward the HER2-low category, typically defined as immunohistochemistry (IHC) 1+ or IHC 2+ with negative in situ hybridization (ISH). This narrative review integrates evidence from the peer-reviewed literature, current testing recommendations, and registered clinical trials. It clarifies practical issues in HER2-low assessment and maps the evolving therapeutic landscape of HER2-targeted ADCs including rational combination strategies that may extend benefit beyond conventionally HER2-positive tumors. A cross-tumor perspective contrasts GC/GEJ testing and biology with the breast cancer paradigm and summarizes the importance of HER2-low expression in non-gastric malignancies. Finally, we discuss the therapeutic strategies in HER2-low GC/GEJ and highlight key safety and monitoring considerations for HER2-directed ADCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania.
- 2nd Clinic of Surgery, Mureș County Emergency Clinical Hospital, 540136 Targu Mures, Romania.
- Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania.
- Department of Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania.
- Romanian Academy of Medical Sciences, 030167 Bucuresti, Romania.
- Szegedi Tudományegyetem, Szent-Györgyi Albert Klinikai Központ, Sebészeti Klinika, 6725 Szeged, Hungary.
ORCID-Profile: Alexandra Georgiana Scurtu, Zsolt Zoltán Fülöp, Simona Gurzu
Förderung
- FOCUS: Training and Guidance for UMFST Researchers in Health
- European Union
Zitieren
APA
Scurtu, A. G., Sala, D. T., Jung, I., Bara, T., Neagoe, R. M., Fülöp, Z. Z., & Gurzu, S. (2026). HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies. International Journal of Molecular Sciences, 27(11), 4673. https://doi.org/10.3390/ijms27114673
Vancouver
Scurtu AG, Sala DT, Jung I, Bara T, Neagoe RM, Fülöp ZZ, et al. HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies. International Journal of Molecular Sciences. 2026;27(11):4673. doi:10.3390/ijms27114673
BibTeX
@article{Scurtu2026,
author = {Scurtu, Alexandra Georgiana and Sala, Daniela Tatiana and Jung, Ioan and Bara, Tivadar and Neagoe, Radu Mircea and Fülöp, Zsolt Zoltán and Gurzu, Simona},
title = {HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {11},
pages = {4673},
doi = {10.3390/ijms27114673}
}
EUVIMED